Cancer

Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia.
A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.
Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
FDA
The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
FDA
The FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.
When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
PRESS RELEASES